This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Align Technology (ALGN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 4.20% and 0.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Should iShares Morningstar Mid-Cap Growth ETF (JKH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKH
Medical Products Q3 Earnings on Oct 24: BSX, ALGN & More
by Zacks Equity Research
Long-term potential of the Medical Products industry appears promising at the moment amid certain short-term geopolitical insecurities.
Can Overall Growth Drive Align Technology (ALGN) Q3 Earnings?
by Zacks Equity Research
Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q3.
Align Technology (ALGN) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Align Technology (ALGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bear of the Day: Newmont Mining (NEM)
by Kevin Cook
Gold back above $1200 is encouraging for miners, but the long-term bear market is still in charge
Why the Earnings Surprise Streak Could Continue for Align Technology (ALGN)
by Zacks Equity Research
Align Technology (ALGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Continued strength in Align Technology's (ALGN) Invisalign volumes impresses. Overdependence on Invisalign Technology system is a concern.
Medical - Dental Supplies Outlook: Long-Term Prospects Bright
by Zacks Equity Research
The ongoing digital transition is posing challenges to dental industry players in the wake of growing oral hygiene awareness and increasing incidence of dental diseases.
Nasdaq ETF Hits New Highs: 5 Stocks Up More Than 50%
by Sweta Killa
Though most of the stocks in the Nasdaq ETF portfolio delivered strong returns so far this year, a few were the real stars, having gained more than 50%.
Align Technology (ALGN) Up 0.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Align Technology (ALGN) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Align Technology International Growth Solid, Rivalry Rife
by Zacks Equity Research
Align Technology's (ALGN) Invisalign Technology prospects and growth in North America and outside hold great potential for the stock, particularly in the Asia-Pacific and EMEA regions.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally.
Bio-Rad (BIO) Banks on Blood Typing Market Amid Margin Woes
by Zacks Equity Research
Bio-Rad (BIO) actively expands portfolio for blood typing market; declining gross margin a concern.
Should iShares Morningstar Mid-Cap Growth ETF (JKH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKH
STERIS (STE) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q1.
Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.
Bio-Rad (BIO) Tops Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Bio-Rad's (BIO) solid growth in North America, China and Asia Pacific reflects strong international foothold in Q2.
CVS Health's (CVS) Q2 Earnings Beat Estimate, Margins Up
by Zacks Equity Research
CVS Health (CVS) reports strong Pharmacy Services revenues, benefiting from the upside in the specialty services. Year-over-year Retail/LTC comparisons are also encouraging.
BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.
Penumbra (PEN) Q2 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q2.
Teleflex (TFX) Q2 Earnings Top, Sales Lag, '18 View Bearish
by Zacks Equity Research
Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.
Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALGN) Outperforming Other Medical Stocks This Year?
Henry Schein's (HSIC) Q2 Earnings Beat, '18 EPS View Up
by Zacks Equity Research
All four of Henry Schein's (HSIC) operating segments recorded strong year-over-year growth in Q2.